Skip to main content

Remote Job Finders (RJF)

Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 18–20% royalties on net sales.
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
Scroll to top